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Abstract 
Glutamate is the principal excitatory neurotransmitter in the central nervous system and its 
actions are related to the behavioral effects of psychostimulant drugs. In the last two decades, 
basic neuroscience research and preclinical studies with animal models are suggesting a critical 
role for glutamate transmission in drug reward, reinforcement, and relapse. Although most of 
the interest has been centered in post-synaptic glutamate receptors, the presynaptic synthesis of 
glutamate through brain glutaminases may also contribute to imbalances in glutamate 
homeostasis, a key feature of the glutamatergic hypothesis of addiction. Glutaminases are the 
main glutamate-producing enzymes in brain and dysregulation of their function have been 
associated with neurodegenerative diseases and neurological disorders;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
however, the possible implication of these enzymes in drug addiction remains largely unknown. 
This mini-review focuses on brain glutaminase isozymes and their alterations by in vivo 
exposure to drugs of abuse, which are discussed in the context of the glutamate homeostasis 
theory of addiction. Recent findings from mouse models have shown that drugs induce changes 
in the expression profiles of key glutamatergic transmission genes, although the molecular 
mechanisms that regulate drug-induced neuronal sensitization and behavioral plasticity are not 
clear. 
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Brain glutaminases 
The mammalian glutaminase (GA; EC 3.5.1.2) family members are encoded by two paralogous 
genes, Gls and Gls2, presumably derived from a common ancestral gene by duplication and 
divergent evolution [1,2]. In humans, the GLS gene is located on chromosome 2 and encodes 
GA isozymes classically referred to as kidney-type (K-type), while GLS2 is located on 
chromosome 12 and codes for liver-type (L-type) isozymes [3]. Orthologous genes have been 
described in rat [4] and mouse [5]. The human GLS gene spans 82 kb and is split into 19 exons 
[1]. Two different transcripts arise from this gene: the KGA transcript, originally found in 
kidney, composed by 18 exons and formed by joining exons 1 to 14 and 16 to 19, and the GAC 
transcript which appears by alternative splicing and uses only the first 15 exons [1,6]. The 
human GLS2 gene has a length of approximately 18 kb and is split into 18 exons [2]. Two 
transcripts have been identified from the mammalian Gls2 gene: the canonical long transcript 
termed GAB, formed by joining all 18 exons of the gene [2], and the short transcript LGA that 
lacks exon 1 and was originally identified in rat liver [7]. 
KGA was originally thought as the only glutaminase present in brain [8,9]. Nowadays, 
the pattern of GA expression in mammalian tissues has been shown to be considerably more 
complex. Concretely, we first reported that human brain expresses GLS2 transcripts, in addition 
to the KGA isoform; these transcripts were ubiquitously expressed in brain regions with the 
strongest signal appearing in cerebral cortex [3,10]. Shortly after, Northern analysis and 
immunocytochemistry in brain of diverse mammalian species (human, monkey, rat, cow, mouse 
and rabbit) confirmed simultaneous expression of GLS (KGA) and GLS2 (GAB and/or LGA) 
isoenzymes; interestingly, both isoforms colocalize in numerous cells throughout the brain [11]. 
Furthermore, the existence of alternative transcripts of the Gls2 gene was recently demonstrated 
in brain (and liver) of three mammalian species: human, rat and mouse [12]. Two GLS2 
transcript variants showing alternative first exons were amplified: the long GAB transcript, 
previously cloned from ZR-75 breast cancer cells [10], and the short LGA transcript first 
characterized in rat liver [4,7]. The LGA variant appears by use of an alternative transcription 
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start site (TSS): both the TSS and one LGA-specific alternative promoter are located in the first 
intron of the Gls2 gene, which is located 7 kb away from the canonical promoter of the GAB 
isoform [12]. Quantitative measurements of GLS2 transcript variants by real-time RT-PCR 
demonstrated that the ratio of the two products varied very widely between tissues and species 
[12]. Thus, while LGA was slightly more abundant than GAB in mouse brain, the opposite was 
found in rat brain where GAB mRNA level was fourfold the amount of LGA. In human brain 
tissue and cultured neurons and astrocytes, KGA and GAC transcripts showed similar 
expression levels [13]. In mammalian brain, evidence supporting expression, at the protein 
level, of the four different GA mRNAs (KGA, GAC, GAB and LGA) has been obtained for all 
of them except for GAC isozyme, by employing isoform-specific antibodies against whole 
proteins, truncated proteins and peptide sequences (reviewed in [14]).  
Glutamine is an important precursor for glutamate synthesis in the brain through GA 
reaction [15,16]. GA is both an important contributor to the transmitter pools of glutamate [16] 
and the main glutamine-utilizing enzyme in neurons [15]. For this reason, GA is regarded as the 
main producer enzyme of presynaptic glutamate in the brain. Various regions specifically 
involved in glutamatergic transmission, such as the cerebral cortex, hippocampus, striatum and 
cerebellum, were emphasized as those presenting the more intense GA immunolabeling [17]. 
The identification of the function of each GA isozyme is essential for understanding their roles 
in cerebral function. Interestingly, GLS2 isoenzymes were not only expressed in neuronal cells, 
but also were found in astrocytes [18,19]. Besides its roles in neurotransmission and 
metabolism, glutamate biosynthesis has been shown to regulate synaptic plasticity, 
neurogenesis, neurite outgrowth, and neuron survival in the developing and adult mammalian 
nervous system [20]. Of note, altered glutamate/glutamine homeostasis has been also involved 
in the pathogenesis of neuropsychiatric diseases [21]. However, the role of presynaptic 
glutamate biosynthesis in the addictive process to drugs of abuse has been considerably less 
studied. 
Glutamatergic theory of addiction 
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The brain reward circuitry includes midbrain dopaminergic neurons in the ventral tegmental 
area (VTA) and the brain regions that are innervated by projections from the VTA, mainly the 
nucleus accumbens (NAc), the prefrontal cortex (PFC), the amygdala, and the hippocampus 
[22], as well as descending feedback projections. This mesocorticolimbic circuit is responsible 
for reward and reinforcement processing and for changing behaviors in response to motivations, 
emotions, affective information and environmental cues that can acquire secondary reinforcing 
properties when paired to repeated drug exposure [23]. The feedback descending projections is 
composed by the cortical projections to the extended amygdale (the amygdala, the NAc and the 
septum, all innervated by the VTA dopaminergic neurons), and the motor subcircuit, that 
includes prefrontal and motor cortex projections to the dorsal striatum and that is innervated by 
the substantia nigra dopaminergic neurons [24]. Both cortical and limbic nuclei send major 
glutamatergic projections to the NAc, which is subdivided into the shell and core subregions; 
the NAc sends GABAergic projections to the VTA/substantia nigra which, in turn, sends 
GABAergic projections to the medial dorsal thalamus (mDT); finally, glutamatergic projections 
from the mDT to the mPFC close the limbic circuit [25]. Thus, the NAc represents a functional 
interface between limbic and motor systems and receives a substantial input of glutamatergic 
afferents that are regulated by dopaminergic projections from the VTA. 
Sound evidences obtained from the 1970s have now generated a general consensus in 
the field of drug addiction pointing to the dopamine (DA) system as the initial target of all 
addictive drugs [26]. Drugs of abuse interact with the mesocorticolimbic nuclei, increasing DA 
levels in this system [27]. However, the increase in DA levels occurs by different mechanisms 
and seems to be drug-specific [28]. Thus, the dopamine hypothesis of addiction has established 
that the strong activation of mesolimbic dopamine is a pervasive and defining feature of all 
addictive drugs. However, while the requirement for increased DA may explain the acute 
reinforcing effects of addictive drugs, it does not provide an explanation for long-lasting 
behavioral abnormalities, like craving and relapse, which are key features of addiction seen 
even when drugs have been cleared from the body and DA levels returned to normal. Therefore, 
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changes in DA signaling cannot be the cause of adaptive behavior which manifest long after the 
drugs have been cleared from the brain (reviewed in [26, 29]). Accordingly, drug-evoked 
changes in concrete neurotransmission circuits of the mesocorticolimbic region were suggested 
to play a causal role in the pathological behavior of addictive patients [30]. Although many 
types of synapses can be modified by addictive drugs, the focus has been centered on various 
forms of synaptic plasticity exhibited by glutamatergic transmission in the circuits of the 
mesolimbic system [31]. Preclinical evidences obtained from studies with rodent models of 
addiction put forward the glutamate homeostasis hypothesis of addiction, which essentially 
proposes the existence of neuroplasticity changes elicited by an imbalance between synaptic and 
non-synaptic glutamate in corticostriatal circuits that undermines connections between PFC and 
NAc, yielding a lower capacity to inhibit drug-seeking behavior and increasing vulnerability to 
relapse [24]. In fact, two types of effects on glutamatergic projections to the NAc are now being 
considered in addiction: slow and enduring changes elicited by the chronic drug use [32], which 
are a major regulator of the addictive behavior and yield persistent neuroadaptations recently 
coined as constitutive synaptic potentiation [33], and rapid transient increases in synaptic 
strength of glutamatergic synapses between PFC afferents in medium spiny neurons (MSN) of 
the NAc core, termed transient synaptic potentiation, which reflect dynamic plasticity changes 
associated with drug seeking neuropathology and relapse [32, 33]. The constitutive adaptations 
are seen after extended withdrawal from chronic drug use, while transient changes are produced 
during cue- or drug-induced reinstatement of drug seeking [33]. 
Glutamate is the main excitatory neurotransmitter in the mammalian central nervous 
system [34]. Furthermore, over 90% of the whole synapses are glutamatergic [35] and the 
Glu/Gln cycle between neurons and astrocytes have been postulated as a central regulatory 
motif for glutamate (and glutamine) homeostasis in brain [36,37]. Glutamate homeostasis also 
involves the regulation of extracellular glutamate levels in the synaptic and perisynaptic 
environments; interestingly, these glutamate pools modulate synaptic strength and plasticity 
through interactions with ionotropic and metabotropic glutamate receptors and are essentially 
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modified by most drugs of abuse (Fig. 1). Thus, in acute and chronic treatments with cocaine, 
heroin and nicotine, as well as in reinstatement by acute drug intake or environmental cues 
associated to drug exposure, marked alterations of extracellular glutamate levels occurs in the 
NAc, striatum, PFC and VTA regions [28,38]. These changes can be of different magnitude and 
range (increments or reductions) depending of the type of drug treatment and withdrawal 
schedule. In this regard, one of the best characterized glutamatergic transmission changes has 
been reported in the NAc region. Acute administration of cocaine has a null or negligible effect 
on extracellular glutamate levels in the NAc [39]; in sharp contrast, withdrawal from chronic 
exposure reduces basal extracellular glutamate levels in the NAc [25]. Interestingly, a challenge 
injection of cocaine during extended withdrawal decreased presynaptic glutamate content in the 
NAc core but not in the NAc shell, suggesting different neuroadaptations in both subregions [25 
and references therein]. In fact, two parallel pathways in the control of drug craving have been 
previously proposed: the prelimbic cortex to NAc core pathway, which promotes drug-seeking 
behavior, and the infralimbic cortex to NAc shell pathway, which is responsible for the 
extinction of drug-seeking behavior [40].           
The impared glutamate homeostasis in the corticostriatal circuitry can be explained by 
drug-induced presynaptic and glial adaptations giving rise to maladaptive synaptic plasticity. 
For example, the decrease in basal accumbal glutamate during withdrawal from chronic cocaine 
exposure, mentioned above, resulted from reduced activity of the cystine-glutamate antiporter. 
The main source of extracellular glutamate in this region came from the activity of the 
astrocytic Xc- cystine-glutamate antiporter, which exchanges extracellular cystine by 
intracellular glutamate with a 1:1 stoichiometry [41]. Repeated cocaine administration 
downregulates the glial Xc- exchanger leading to the reduced basal extracellular glutamate 
levels in the NAc, frequently observed in animal models of addiction [24,41] (Fig. 1). 
Therefore, the NAc core synapse shows a fall in the pool of non-synaptic glutamate at the 
extracellular space following both chronic administration and withdrawal from addictive drugs, 
like cocaine and methamphetamine [42]. Of note, activating the Xc- antiporter with N-
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acetylcysteine restores basal extracellular levels of glutamate and prevents the reinstament of 
cocaine and heroin seeking [24,41]. The decreased extrasynaptic glutamate concentration 
induces an enhanced release of synaptic glutamate in the NAc core through inactivation of 
presynaptic inhibitory metabotropic glutamate mGluR2/3 receptors [32] (Fig. 1). The reduction 
in mGluR2/3 autoreceptor signaling arises by downregulation of protein expression, as well as 
by upregulation of activator of G protein signaling 3 (AGS3) which inactivates Giα subunit 
[33].   The lack of tone on metabotropic mGluR2/3 receptors potentiates the synaptic release of 
glutamate. Accordingly, direct agonist stimulation of mGluR2/3 inhibits cocaine and heroin 
seeking [24]. The overflow of synaptic glutamate was attenuated by pharmacological 
inactivation of the mFPC [43], whereas administration of AMPA (α-amino-3-hydroxy-5-
methyl-4-isoxazole propionic acid) receptor antagonists into the NAc blocked the reinstatement 
of cocaine seeking [44]. Taken together, these findings strongly suggest that activation of 
glutamatergic projections from the mPFC to the NAc, along with stimulation of AMPA 
receptors, play a critical role in cocaine seeking, in agreement with brain imaging studies of 
human cocaine addicts showing metabolic activation of the mPFC during cocaine craving [45].  
In addition, another drug-induced glial adaptation essentially contributes to the 
heightened synaptic glutamate levels in the NAc: the abnormally high amount of glutamate 
released in the synaptic cleft is not efficiently removed, because the glial excitatory amino acid 
transporter GLT-1 (EAAT2) is also downregulated in the NAc following chronic exposure to 
cocaine, nicotine, ethanol, and heroin (extended withdrawal from cocaine causes further 
silencing) [42]. Therefore, synaptic glutamate levels are increased owing to enhanced release 
and to reduced elimination from the extracellular space. Interestingly, the enhanced synaptic 
glutamate release in the NAc was also observed during the reinstatement of extinguished drug 
seeking, provoked by exposure to drug-associated cues, stress or drug itself. Thus, enhanced 
levels of extracellular NAc glutamate due to an increased presynaptic release were found during 
the reinstatement of cocaine, nicotine, methamphetamine, heroin and alcohol [24,42,46-48]. 
These excessive glutamate amounts and overflow of synaptic glutamate during reinstatement 
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may explain how drug-associated cues provoke such a strong behavioral effect. This glutamate 
overflow causes spillover and additional activation of synaptic (AMPA, NMDA (N-methyl-D-
aspartate) and nonsynaptic glutamate receptors, particularly ionotropic GluN2B containing 
NMDA receptors and metabotropic mGluR5 receptors [33,42]. 
A final consequence of drug-induced changes in NAc glutamatergic transmission is the 
postsynaptic remodeling that induces structural plasticity, giving rise to constitutive synaptic 
potentiation. Glutamatergic synaptic plasticity has been described in dopamine D1R neurons 
and GABAergic MSN during prolonged drug exposure, withdrawal and cue-induce relapse to 
drug seeking (see [28] and [49] for a review). For example, during cocaine, nicotine and heroin-
reinstatement there were increases in dendritic spine head diameter and AMPA receptor currents 
due to a shift in the AMPA/NMDA ratio [32,46,50]; these are typical characteristics of a long-
term potentiation (LTP) state (Fig. 1). Furthermore, it is well known that the number of 
dendritic spines on NAc MSN increases after repeated exposure to cocaine, amphetamine and 
nicotine [51]. Many studies have demonstrated the relevance of dendritic spine morphology in 
hippocampus and cerebral cortex; concretely, their size and shape correlate with different forms 
of synaptic plasticity such as LTP and long-term depression (LTD) [52]. Furthermore, 
stimulants like cocaine, amphetamine and methylphenidate consistently increase dendritic 
complexity and spine density of MSN in the NAc, dopaminergic neurons in the VTA and 
pyramidal neurons of the mPFC [49]. Of note, the drug-evoked synaptic plasticity in the NAc 
has been recently proposed as a causal mechanism controlling cocaine relapse [53]. 
On the other hand, a neuroproteomic study in rats with self-administration of cocaine 
found significant changes in proteins related to synapse function and neuronal remodeling; 
curiously, a number of them remained altered even after long periods (100 days) of abstinence 
[54]. Moreover, results from proteomic studies of the NAc in monkeys following chronic 
cocaine self-administration found quantitative differences in proteins involved in cytoskeleton 
structure and remodeling, mitochondrial function, energy metabolism and cell signaling [55]. A 
significant number of these proteins were either directly or indirectly related to the 
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hyperglutamatergic state identified in rhesus monkeys self-administered with cocaine and also 
in cocaine overdose victims [56]. In addition to the Xc- exchanger, extracellular glutamate is 
derived from vesicular synaptic and non-vesicular glial release. While the expression of the glial 
GLT-1 transporter has been shown to be diminished following exposure to drugs, scarce 
information was available regarding the effect of drug of abuse on the regulation of presynaptic 
glutamate synthesis, via glutaminase, and its relevance in the activation of glutamatergic 
transmission and synaptic plasticity associated with craving and relapse after drug withdrawal.  
Glutaminases and drug addiction 
The regulation of presynaptic glutamate synthesis and release may also contribute to 
drug craving and relapse to drug seeking. Changes in neurotransmitter release are thought to 
underlie the decreased inhibitory modulation of pyramidal neurons in the PFC during early 
withdrawal from repeated cocaine exposure; however, this attenuation in inhibitory transmission 
seems to be shifted at the glutamate receptor level during more prolonged withdrawal [57]. 
Therefore, we aimed to ascertain whether GA isoforms would also contribute to trigger 
pathophysiological release of synaptic glutamate, a frequent alteration observed in animal 
models of cocaine addiction. While glutamate receptors, namely metabotropic, and their ligands 
are well documented to be potential therapeutic targets for addiction [26,42], GA had not been 
investigated in almost two decades since it was studied for the physical dependence upon and 
tolerance to opiates [58]. It was previously shown that subchronic and acute administration of 
GA inhibitor prolyl-leucyl-glycinamide (PLG) modulates morphine physical dependence by 
inhibition of glutamate production, an effect consistent with the hypothesis of dependence to 
opiates which states that these drugs inhibit GA in the nerve ends [59]. Interestingly, acute 
administration of inhibitors of glutamate release, such as tizanidine, attenuated the abstinence 
syndrome to opiates, as did PLG; this effect was explained by the lesser release of glutamate 
and, concomitantly, the lesser activation of receptors [58]. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
11 
 
 
More recently, the GA inhibitor PLG was employed in studies dealing with the role of 
neuron-glial related cell adhesion molecule (NrCAM) in addiction vulnerability for 
polysubstance abuse. NrCAM is a regulator of axon growth, dendritic spine remodeling and 
hippocampus development, and has been associated with drug abuse vulnerability in humans 
and mice [60,61]. Nrcam knockout (KO) mice were generated in order to gain insight into 
NrCAM protein involvement in addiction; interestingly, expression of Gls, a key glutamatergic 
gene coding for K-type GA isoforms, was significantly downregulated in PFC and ventral 
midbrain regions in heterozygous mice compared with wild-type littermates. This unexpected 
finding was also confirmed in T98G human glioblastoma cells treated with siRNA against the 
NRCAM gene: characterization of their transcriptome by microarray analysis revealed that GLS 
was downregulated more than 50% in cells with silenced expression of NrCAM [62]. Decreased 
NrCAM expression in brain is protective against addiction vulnerability: Nrcam KO mice do 
not develop conditioned place preferences for morphine, cocaine or amphetamine [60]. Similar 
phenotypes were produced in mice treated with the GA inhibitor PLG [62], in accordance with 
this effect being mediated by altered presynaptic glutamate synthesis. Hence, these authors 
conclude that NrCAM regulates addiction-related behaviors at least partially through regulation 
of GA (Gls) expression, reinforcing the glutamate homeostasis theory of addiction. 
The genomic dysfunctions induced by acute and chronic cocaine administration in the 
glutamatergic system were recently characterized by analyzing the expression of genes involved 
in the biosynthesis and transport of glutamate in mouse brain. We assessed the short/long-term 
mRNA modifications caused by differences in acute treatment (vehicle or cocaine for 1 day), 
chronic pretreatment (conditioning with vehicle or cocaine for 5 days) and its interaction (acute 
treatment x chronic pretreatment) (Fig. 2). In this way, we had four experimental groups: 
animals conditioned with cocaine (20 mg/Kg) and administered with vehicle or cocaine (10 
mg/Kg), and animals conditioned with vehicle and treated with vehicle or cocaine (10 mg/Kg) 
(Fig. 2). The expression profiles of genes coding for the neuronal excitatory amino acid carrier 1 
(EAAC1) and enzymes of glutamate synthesis (KGA and GLS2 GA isoforms) in striatum, 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
12 
 
 
hippocampus, prefrontal cortex and cerebellum of treated-mice were analyzed [63]. The results 
showed that acute administration of cocaine resulted in a dose-dependent increase of locomotor 
activity, while chronic treatment induced conditioned locomotion and behavioral sensitization. 
Changes in mRNA levels of GA isoforms and neuronal glutamate transporter EAAC1 (EAAT3) 
were observed: the strongest effects were mostly seen after acute cocaine challenge. Regarding 
the EAAC1 carrier in striatum, our data showed statistically significant decreased expression 
after acute cocaine, in both control (V-C group) and cocaine-sensitized animals (C-C group) 
(Fig. 2), suggesting that this neuronal Glu transporter plays also a role in the neuroadaptations to 
cocaine. Thus, its downregulation might also contribute to the known increase of synaptic 
accumbal glutamate and glutamatergic signaling, through regulation of pre-synaptically released 
glutamate during withdrawal from cocaine exposure [63]. In case of the EAAC1 transporter 
mRNA expression in cerebellum, we observed a chronic effect induced by chronic pretreatment, 
but not by acute treatment (Fig. 2). This enhancement in the levels of Glu transporter mRNA 
could be due to initial chronic pretreatment with cocaine in Purkinje cells where the EAAC1 
transporter is especially abundant. The remaining regions studied, hippocampus and PFC, did 
not present differences in expression levels [63]. 
KGA mRNA expression is activated by chronic-cocaine pretreatment in striatum, but 
did not show significant differences in acute treatment (Fig. 3). Repeated administration of 
cocaine produced long-term overstimulation throughout the increased neuronal excitability of 
glutamatergic striatal neurons. This neural excitation may be caused by an enhanced KGA 
enzymatic activity related to an augmented locomotion induced by cocaine conditioning and is 
consistent with the glutamate homeostasis hypothesis of addiction. Instead, KGA mRNA 
expression in hippocampus is inhibited by both acute- and chronic-cocaine treatments (Fig. 3) 
[63-64]; however, since non-statistically significant differences were found between both 
groups, this reduced expression could not be ascribed to cocaine sensitization. The decrement of 
hippocampal KGA gene expression can be linked to the lower gene expressions of metabotropic 
mGluR3 and GluR5 glutamate receptors and GluN1, GluN2A, GluN2B and GluN2C NMDA 
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receptor subunits following acute cocaine administration [64]. Interestingly, locomotor 
sensitization to cocaine was specifically associated with an increased gene expression of GluN1 
and GluN2C NMDA receptor subunits [64].  
On the other hand, GLS2 mRNA expression is strongly activated by cocaine in the 
striatal region after chronic injection protocols (Fig. 3); we found an interaction between acute 
and chronic treatments which suggest this effect might be due to robust cocaine-induce neuronal 
sensitization. In the PFC, GLS2 mRNA increases in acute cocaine priming, as well as in acute 
cocaine/sensitized mice (Fig. 3) [63,65], while its expression levels remain essentially 
unchanged in hippocampus and cerebellum [63,64] (although in this last region, a significant 
increase was detected for the C-C group vs the V-V group [66]). It is noteworthy that both GA 
isoforms showed a strikingly different pattern in the cocaine addiction paradigm described 
above. This markedly distinct regulation of GA isoforms by cocaine would be related to their 
different roles, recently unveiled for GLS and GLS2 isoenzymes. Thus, novel GA tasks include 
neuronal development and maturation for KGA isozyme, and transcriptional regulation, 
associated with its nuclear localization, for GLS2 isoforms [14]. Nevertheless, in terms of 
absolute quantitative levels, KGA mRNA levels are much more abundant than GLS2 (L-type) 
GA in striatum, hippocampus, prefrontal cortex and cerebellum [63], as well as in rat and mouse 
whole brain [12]. These data are consistent with our previous results at the protein level, 
showing that KGA immunostaining was more pronounced in the mammalian brain than GLS2 
[11,18,19]. 
Total GA activity is decreased after repeated exposure (C-V group) to cocaine using a 
dose regimen that induces behavioural sensitization to this psychostimulant: one priming 
injection after chronic administration of cocaine (C-C group) also elicited a decrease in GA 
activity in both the dorsal striatum and the PFC vs V-V or V-C groups (Fig. 3). After chronic 
cocaine pretreatment, neither a vehicle injection nor a challenge with a cocaine injection was 
able to recover the GA activity values to those shown by acute control (V-V) or acute cocaine-
treated (V-C) animals (Fig. 3). Cocaine-induced sensitization is associated to enhance glutamate 
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transmission in both brain areas owing to dynamic changes in both glutamate release and 
glutamate receptor signaling, as we detailed in the previous section. In this context, the decrease 
in GA activity may be either a counter-regulatory inhibition to compensate the enhanced 
glutamate output or be related to the fact that withdrawal from repeated exposure to cocaine 
reduces basal extracellular glutamate levels in the basal ganglia [25]. Since we observed a 
reduced GA activity 5 days after cessation of repeated cocaine exposure, this explanation seems 
to be plausible. Overall, these results set in place GA as a relevant protein involved in the 
neuroadaptations associated to repeated cocaine exposure. Main changes were observed on the 
prefrontal cortex-dorsal striatum circuit, which is the anatomical site for the neuroplasticity 
events that underlie the cocaine-induced behavioral sensitization. The results represent a 
molecular basis to explain the cocaine-induced and region-specific alterations of extracellular 
glutamate in the mesocorticolimbic circuit. Moreover, cocaine affects glutamatergic enzymes 
and transporter with sharply different patterns specific for the brain area under study, inducing 
differential long-lasting effects in striatum glutamate receptors. Furthermore, cocaine may exert 
different roles in pre/postsynaptic neuronal membrane by regulation of glutamate synthesis and 
transport depending on acute or chronic administration regimen. 
Involvement of endocannabinoids and biolipids 
Finally, the role of endocannabinoids (eCB) and bioactive lipids, as modulatory systems 
of glutamatergic neurotransmission in cerebral areas involved in drug addiction, also deserves 
some comments. Glutamatergic transmission is retrogradely modulated by eCB through the 
stimulation of CB1 receptors located in the glutamatergic and GABAergic axon terminals and 
preterminals of the brain [67]. Both acute and repeated cocaine administration modulate the 
expression of the endocannabinoid signaling machinery in PFC, hippocampus and cerebellum. 
For example, after chronic cocaine exposure there is a decreased expression of the eCB-
degradation enzyme fatty acid amino hydrolase (FAAH) and eCB-producer enzyme 
diacylglycerol lipase β (DAGLβ) in mouse cerebellum, suggesting a down-regulation of 2-
arachidonylglycerol (2-AG) production, which is responsible for inhibiting the excitatory 
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glutamatergic inputs of granule cells [66]. The lack of eCB-mediated inhibition might be 
partially responsible for a hyperactivated glutamatergic state in cerebellum (increased 
expression of GLS2 after chronic cocaine pretreatment), similar to the well-described 
hyperglutamatergic state detected in the NAc with prolonged cocaine action [24,33]. Of note, 
results obtained in mouse hippocampus and PFC demonstrated that chronic exposure to cocaine 
resulted in a down-regulation of the endocannabinoid-production/degradation enzyme ratios, 
suggesting a reduced endocannabinoid tone, along with an upregulation of CB1 receptors 
[64,65]. This over-expression of the CB1 receptor could be a compensatory response to 
counteract the low availability of retrograde endocannabinoid inhibitory signals. In conclusion, 
these results indicate that cocaine administration induces a reduced hippocampal and PFC 
endocannabinoid tone which could be linked to a hyperactive glutamatergic signaling. 
On the other hand, it is well documented the role of lysophosphatidic acids (LPA) as 
mediators of learning, emotional behavior and synapse formation through modulation of 
dendritic spine dynamics. Although many types of LPA receptors have been detected in brain, 
LPA1 is abundantly expressed and considered the most prevalent receptor type in both 
embryonic and adult brains [68]. Genetic silencing of LPA1 in mice causes deficiencies in 
spatial memory retention and abnormal use of searching orientation strategies [69], defective 
working and reference memory independently of exploratory and emotional impairments 
attributed to hippocampal malfunction [70]. With regard to drugs of abuse, altered expression of 
hippocampal metabotropic mGLUR3 glutamate receptors and the GLUR1 subunit of AMPA 
receptor were reported in KOLPA1 mice, associated to an attenuated conditioned locomotion 
(CL) response after cocaine conditioning [71]. Furthermore, genetic deletion and 
pharmacological blockade of LPA1 receptor results in increased alcohol consumption in mice, 
suggesting a relevant role for the LPA/LPA1 signaling pathway in alcoholism [72]. 
Interestingly, KOLPA1 mice show a strong downregulation of KGA protein expression mostly 
in cerebral cortex and hippocampus (Authors, manuscript in preparation). The KGA protein 
deficit might be linked to the altered morphology of hippocampal dendritic spines shown by 
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KOLPA1 mice: these animals presented a less mature, filopodia-like, phenotype as compared 
with wild-type littermates. Several protein markers involved in spine maturation were then 
analyzed: both protein expression level and activity of matrix-metalloproteinase 9 (MMP-9) 
were significantly reduced in KOLPA1 mice (Authors, manuscript in preparation). In 
conclusion, LPA signalling through LPA1 strongly influences expression of the main isozyme of 
glutamate biosynthesis (KGA) and has repercussions on dendritic spines architecture, which 
might partially explain the cognitive and learning defects shown by these animals. In this 
regard, it is worth mentioning that synaptic plasticity mediating cocaine relapse also requires 
matrix metalloproteinases [73]; thus, although it is not currently understood how long-lasting 
synaptic potentiation at glutamatergic synapses is required for relapse to drug-seeking, re-
shaping of dendritic spine morphology through LPA1 signaling (and/or brain GA) appears as a 
plausible mechanism supporting long-term corticostriatal glutamatergic plasticity underlying 
drug relapse and drug-seeking behaviors. 
Future directions 
Sound experimental evidences to confirm the causal relationship between altered 
synaptic plasticity in glutamatergic synapses of the corticolimbic system and the drug-seeking 
behavior and relapse are still lacking. In this regard, novel animal models of addiction and the 
new field of optogenetics, where the composition and number of glutamate receptors may be 
controlled by light pulses, can give essential information that will be later validated in human 
studies. Synaptic glutamate spillover during drug seeking is a potential pharmacotherapeutic 
target that seems to appear ubiquitously across drug classes. Therefore, molecules targeting key 
proteins involved in this glutamatergic neuroadaptation have demonstrated a good response by 
reducing drug seeking in animal models; for example, N-acetylcysteine and ceftriaxone through 
activation of the downregulated GLT-1 (EAAT2) transporter, and mGluR2/3 agonists or AGS3 
peptide inhibitors via activation of mGluR2/3 receptor signaling [33].  
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Elucidation of the molecular mechanisms associated with drug-induced 
neuroadaptations will certainly improve the few effective therapeutic options available to date. 
The picture of proteins involved in the control of glutamate homeostasis seems not yet fully 
unveiled; it should include not only postsynaptic receptors, but also proteins participating in the 
presynaptic synthesis of glutamate and its release into the synaptic cleft. In this sense, brain 
glutaminases should be added to the list of novel candidates for the pharmacotherapy of drug 
craving and relapse. However, the lack of potent and specific GA inhibitors with good brain 
penetrant behavior has precluded so far testing GA inhibition in the pharmacotherapy of many 
neurological alterations and diseases. In spite of this limitation, mouse models with defective 
expression of brain GA isoforms have recently demonstrated a strong potential for evaluation of 
GA inhibition therapy in the pharmacotherapy of neuropsychiatric disorders. Remarkably, mice 
with only one functional Gls allele (and with a concomitant reduction in GA activity) showed a 
schizophrenia resilience phenotype [74], while at the same time having a benign side effect 
profile [75]. Therefore, genetic pharmacotherapy appears as a valid alternative for drug 
development strategy against neurological disorders, including addiction, while new and more 
effective GA inhibitors are developed. 
Finally, apart from the classic route of glutamate synthesis, release and clearance at the 
synapsis, other neurotransmitters, such as endocannabinoids and neuroactive lipids, can 
modulate glutamatergic transmission and may become relevant pieces in the puzzle of addictive 
behaviors to drugs of abuse. 
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FIGURE LEGENDS 
Figure 1. Altered glutamatergic transmission in cocaine addiction. This scheme illustrates 
the regions involved in the corticostriatal brain reward circuitry. The main glutamatergic 
neuroadaptations (changes in glutamatergic synapses) in cerebral regions closely connected to 
the addictive behavior to stimulant drugs are indicated. Although most of these variations were 
characterized for cocaine, some of them, as explained in the article, are also shared by other 
stimulant drugs such as heroin, nicotine, morphine and alcohol. Relevant adaptations include 
altered extracellular glutamate levels (increases or reductions depending on the region and type 
of addiction paradigm), changes in the expression of neuronal and glial glutamate transporters  
and postsynaptic plasticity (variations in the AMPAR/NMDAR ratio, dendritic spine 
morphology and/or number and activity of MMPs). Arrows indicate relevant drug-induced 
synaptic changes that promote neuroadaptations in the NAc leading to increased synaptic 
strength. The potentiation of GABAergic synapses in the VTA region is also indicated at the top 
of the figure. GA, glutaminase; GABAT, GABA transaminase; SSA, succinic semialdehyde; 
GAD, glutamate decarboxylase; PLP, pyridoxal 5’-phosphate; KA, kainate receptors; M, 
metabotropic glutamate receptors. 
 
Figure 2. Protocol employed to evaluate cocaine-induced conditioned locomotion (CL), 
locomotor sensitization (LS) and gene expression modifications of the glutamate carrier 
EAAC1. Top panel: schematic representation of the consecutive 5-phase-paradigm for 
acquisition and expression of cocaine-induced sensitization. Following two days of handling, 
mice were daily administrated i.p. with vehicle or cocaine (20 mg/Kg) during five consecutive 
days (pretreatment, cocaine conditioning). In the next 5 days, all animals rested without the drug 
(no-treatment, days 8-12). On day 13, half of the mice pretreated with vehicle and half of the 
mice pretreated with cocaine were treated i.p. with vehicle to evaluate conditioned locomotion 
(CL) response. Finally, on the last day (14), the remaining half of the mice pretreated with 
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vehicle and the remaining half of the mice pretreated with cocaine were treated i.p. with a lower 
dose of cocaine (priming, 10 mg/Kg) to assess locomotor sensitization (LS) response. These 
independent groups of animals (chronic cocaine pretreatment + acute vehicle treatment, C-V 
group; chronic cocaine pretreatment + acute cocaine treatment, C-C group; chronic vehicle 
pretreatment + acute vehicle treatment, V-V group; and chronic vehicle pretreatment + acute 
cocaine treatment, V-C group) were employed by gene and enzymatic glutaminase activity 
studies. Bottom panel: quantitative real-time RT-PCR analysis of EAAC1 mRNA expression 
normalized to the levels of β-actin mRNA in different brain regions. Each value corresponds to 
mRNA levels in C57BL/6J mice after acute treatment (sensitization with vehicle or cocaine for 
1 day) and chronic pretreatment (conditioning with vehicle or cocaine for 5 days). Bars indicate 
the mean value + SEM (n=7-8 per group). Two-way ANOVA, *p <0.05 chronic pretreatment 
effect in cerebellum; **p<0.01 acute treatment effect in striatum; **p<0.01 chronic 
pretreatment effect in striatum (adapted from reference [63]). 
Figure 3.  Assessment of GA mRNA and enzymatic activity modifications caused by acute 
cocaine treatment (vehicle or cocaine for 1 day), chronic cocaine pretreatment 
(conditioning with vehicle or cocaine for 5 days) and its interaction (acute treatment x 
chronic pretreatment). Top panel: quantitative real-time RT-PCR analysis of KGA mRNA 
expression normalized to the levels of β-actin mRNA in different brain regions. Each value 
corresponds to mRNA levels in C57BL/6J mice after acute treatment (sensitization with vehicle 
or cocaine for 1 day) and chronic pretreatment (conditioning with vehicle or cocaine for 5 days). 
Bars indicate the mean value + SEM (n=7-8 per group). Two-way ANOVA: *p<0.05 chronic 
pretreatment effect in striatum, ***p<0.001 acute treatment in hippocampus; Bonferroni post 
hoc analysis: ##p<0.01 vs. V-V group in hippocampus, #p<0.05 vs. V-V group in PFC and 
cerebellum, Ѕp<0.05 vs. C-V group in hippocampus. Medium panel: quantitative real-time RT-
PCR analysis of GLS2 mRNA expression normalized to the levels of β-actin mRNA in different 
brain regions. Each value corresponds to mRNA levels in C57BL/6J mice after acute treatment 
(sensitization with vehicle or cocaine for 1 day) and chronic pretreatment (conditioning with 
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vehicle or cocaine for 5 days). Bars indicate the mean value + SEM (n=7-8 per group). Two-
way ANOVA: **p<0.01 interaction (acute treatment x chronic pretreatment effect) in striatum, 
*p<0.05 acute treatment effect in PFC; Bonferroni post hoc analysis: #p<0.01 vs. V-V group in 
PFC and cerebellum. Bottom panel: quantification of total enzymatic activity of GA in striatum 
(a) (n=6), hippocampus (b) (n=6) and PFC (c) (n=6) after acute treatment vs. chronic 
pretreatment with vehicle and cocaine in mice. Two-way ANOVA: *p<0.05; ***p<0.001 
(adapted from references [63-66]). 
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